Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of pioglitazone on insulin sensitivity and function of pancreatic α and β cells in type 2 diabetic patients with different body weight

Trial Profile

Effects of pioglitazone on insulin sensitivity and function of pancreatic α and β cells in type 2 diabetic patients with different body weight

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Apr 2018

At a glance

  • Drugs Pioglitazone (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Apr 2018 Results assessing effects of pioglitazone (PIO) on insulin resistance and first phase insulin secretion among obese and lean Chinese people with type 2 diabetes mellitus, were published in the Diabetes Therapy.
    • 13 Jun 2017 Results assessing insulin sensitivity and pancreatic cell function presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 07 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top